Autologous TIL Cell Therapy: A Potential Next Line of Treatment for HNSCC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
A phase 2 study reveals autologous TIL therapy's potential to stabilize recurrent head and neck cancer, offering hope for improved treatment options.| www.targetedonc.com
